Recent developments in cervical cancer screening methods and updated guidelines aim to enhance early detection and reduce the incidence of cervical cancer, a disease that remains a significant cause of mortality worldwide. Despite advances in prevention through human papillomavirus (HPV) vaccination and screening, cervical cancer continues to claim over 250,000 lives annually, including approximately 4,000 deaths in the United States.

Cervical cancer screening traditionally relied on the Pap smear, a cytology-based test in which cervical cells are collected by clinicians and examined for precancerous or cancerous changes. While this approach remains widely used, recognition of the role of HPV—a common viral infection linked to nearly all cervical cancers—has led to new testing possibilities. HPV testing can be conducted on samples collected either by clinicians from the cervix or by patients themselves from the vagina.

The U.S. Food and Drug Administration approved self-collection devices for HPV testing in clinical settings in 2024, with home use anticipated to be authorized in 2025. Studies indicate that self-collected samples are comparably accurate to those taken by clinicians, potentially addressing barriers such as discomfort with pelvic exams and limited access to healthcare facilities that have historically contributed to screening disparities.

Screening recommendations vary by age and organization. For individuals aged 30 and older—including women and transgender people assigned female at birth—there is broad consensus that HPV testing offers the most sensitive detection, identifying risk earlier than cytology alone. However, screening guidelines differ for younger adults. The American Cancer Society recommends initiating HPV testing at age 25, whereas the American College of Obstetricians and Gynecologists (ACOG) and the Women’s Preventive Services Initiative (W.P.S.I.) suggest cytology screening alone from ages 21 to 29 due to the commonality of transient HPV infections in this group, which often resolve without intervention.

Experts agree that both cytology and HPV testing strategies provide effective cancer prevention. However, differing guidelines reflect varied approaches to balancing the benefits of early detection with the risks of overtreatment. Patients and providers are advised to consider these recommendations within the context of individual risk factors.

Major professional organizations acknowledge that self-collection is an acceptable screening method, while some encourage clinician-collected samples when feasible. A key limitation of self-collected samples is the need for in-person follow-up if HPV is detected, since further tests cannot be performed on the initial self-collected specimen. Without appropriate follow-up, self-collection alone may not improve outcomes. Nevertheless, with proper follow-up, self-collection can significantly increase screening uptake compared to not testing at all.

Screening intervals also differ slightly. ACOG recommends Pap tests every three years from ages 21 to 29 and clinician-collected HPV testing every five years for those 30 to 65. W.P.S.I. mirrors this schedule, while the American Cancer Society advises clinician-collected HPV testing every five years or self-collected HPV testing every three years from ages 25 to 65.

Regarding cessation of screening, guidelines generally concur that it is reasonable to stop after age 65 in patients with an adequate history of negative tests over the prior decade. Specific requirements vary, but consensus reflects the low risk of developing cervical cancer beyond this age window. Experts emphasize the importance of consistent screening leading up to this point, noting that physiological changes with age can make testing more challenging.

Overall, these evolving recommendations and new testing options aim to reduce barriers and improve prevention efforts against cervical cancer, helping to lower its incidence and save lives.